Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Liabilities and Shareholders Equity (2022 - 2025)

Prokidney (PROK) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $351.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 25.94% to $351.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 billion, a 11.86% decrease, with the full-year FY2024 number at $441.1 million, up 4.88% from a year prior.
  • Liabilities and Shareholders Equity was $351.6 million for Q3 2025 at Prokidney, down from $372.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $532.4 million in Q3 2022 to a low of $250.8 million in Q1 2022.
  • A 4-year average of $422.4 million and a median of $441.1 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 97.47% in 2023, then fell 25.94% in 2025.
  • Prokidney's Liabilities and Shareholders Equity stood at $518.0 million in 2022, then fell by 18.81% to $420.6 million in 2023, then rose by 4.88% to $441.1 million in 2024, then dropped by 20.28% to $351.6 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's Liabilities and Shareholders Equity are $351.6 million (Q3 2025), $372.1 million (Q2 2025), and $406.1 million (Q1 2025).